Biocon strong in Q1 despite challenging Indian regulatory environment
This article was originally published in Scrip
Executive Summary
Biocon has reported strong first quarter results and outlined plans for the launch of a first-in-class anti-CD6 monoclonal antibody, itolizumab, for psoriasis, but India's largest biotechnology firm also indicated that the country's challenging regulatory environment was a cause for concern.